OS Therapies Inc (OSTX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.88+3.30%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OSTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
OSTX — debt issuance
Dated 2026-08-21
Entry into a Material Definitive Agreement. On August 21, 2026, OS Therapies Incorporated (the “Company”) entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company’s “at the market offering” program (the “ATM Offering”). On August 21, 2026, the Company filed with the Securities and Exchange…
Why it matters: Approval for OST-HER2 is key for future sales. It could drive revenue growth.
Supportive ifRegulatory approval for OST-HER2 in the UK by Q2-26, US by Q3-26.
Worry ifRegulatory delays or denials for OST-HER2 in the UK or US.
Why it matters: Using this credit wisely could help with ongoing work and growth.
Watch forThe company says it used the $10 million credit line for OST-HER2 development.
Also watch forThe company struggles to use the credit line well, which affects operations.
Why it matters: This refund could provide needed cash flow amid ongoing losses.
Supportive ifManagement confirms receipt of $2M in VAT refunds in Q2-26.
Worry ifNo VAT refunds received as expected in Q2-26.
Why it matters: Updates on cash runway are important for funding operations and trials. Good news can boost investor trust.
Supportive ifManagement says they have enough cash to last until 2027. This is after raising more money.
Worry ifManagement says cash runway is shorter than expected.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $685 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,978 loss on $10,000 · 49.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The FDA meeting is very important. It helps agree on clinical efficacy endpoints for OST-HER2.
Supportive ifThe FDA agrees with the company on clinical goals in the Type B meeting.
Worry ifFDA does not align with the company on the proposed endpoints.
Why it matters: Hitting this sales target is key for the company's growth.
Supportive ifManagement says they are on track for $50M in OST-HER2 sales by 2027.
Worry ifManagement lowers the sales target for OST-HER2 to below $50M.
Why it matters: This data is important for the EMA's review of OST-HER2 and its rules.
Watch for2.5-year overall survival data shows a big gain compared to past results.
Also watch for2.5-year overall survival data does not meet expectations or shows no gain.
Why it matters: How management deals with losses can change how much investors trust them. It can also impact future plans.
Watch forManagement shares a clear plan to cut losses or make more money.
Also watch forManagement does not talk about losses or does not show a recovery plan.
Why it matters: This funding is important. It supports operations and helps advance clinical trials.
Supportive ifThe company successfully draws down the full $10 million line of credit.
Worry ifThe company fails to utilize or secure the line of credit as planned.
Why it matters: Starting the Phase 3 trial is important. It helps with getting approvals and market access.
Supportive ifThe confirmatory Phase 3 trial for OST-HER2 begins as planned in Q3 2026.
Worry ifThe initiation of the Phase 3 trial is delayed beyond Q3 2026.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the company's performance.
Supportive ifRevenue growth speeds up again, getting close to its past highs near 10%.
Worry ifRevenue growth keeps slowing down or stays the same.
Why it matters: The result will show if OS Therapies can apply for a Biologics License for OST-HER2.
Supportive ifFDA meeting shows agreement on how well OST-HER2 works.
Worry ifFDA meeting shows disagreement on how well OST-HER2 works.
Why it matters: The results will help with the Biologics License Application for OST-HER2.
Supportive ifThe FDA provides positive feedback during the Pre-BLA Type B meeting.
Worry ifThe FDA raises significant concerns during the Pre-BLA Type B meeting.
Why it matters: Updates on tax credit cash will show financial health as OS Therapies moves forward.
Supportive ifOS Therapies gets about $4 million in non-dilutive funds from U.K. tax credits.
Worry ifOS Therapies does not get the expected $4 million in non-dilutive funds.